Trade Invivyd Inc. - IVVD CFD
Add to favourite- Summary
- Historical Data
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 0.74 |
Open | 0.73 |
1-Year Change | -51.33% |
Day's Range | 0.67 - 0.74 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Nov 21, 2024 | 0.67 | -0.06 | -8.22% | 0.73 | 0.75 | 0.67 |
Nov 20, 2024 | 0.74 | -0.01 | -1.33% | 0.75 | 0.77 | 0.72 |
Nov 19, 2024 | 0.75 | 0.04 | 5.63% | 0.71 | 0.77 | 0.70 |
Nov 18, 2024 | 0.73 | -0.01 | -1.35% | 0.74 | 0.74 | 0.70 |
Nov 15, 2024 | 0.73 | -0.06 | -7.59% | 0.79 | 0.79 | 0.73 |
Nov 14, 2024 | 0.77 | -0.08 | -9.41% | 0.85 | 0.85 | 0.76 |
Nov 13, 2024 | 0.87 | -0.08 | -8.42% | 0.95 | 0.96 | 0.87 |
Nov 12, 2024 | 0.97 | 0.00 | 0.00% | 0.97 | 0.99 | 0.94 |
Nov 11, 2024 | 0.95 | -0.01 | -1.04% | 0.96 | 0.96 | 0.91 |
Nov 8, 2024 | 0.94 | -0.04 | -4.08% | 0.98 | 0.98 | 0.91 |
Nov 7, 2024 | 0.98 | -0.04 | -3.92% | 1.02 | 1.04 | 0.97 |
Nov 6, 2024 | 1.01 | 0.04 | 4.12% | 0.97 | 1.02 | 0.95 |
Nov 5, 2024 | 0.89 | -0.01 | -1.11% | 0.90 | 0.91 | 0.88 |
Nov 4, 2024 | 0.88 | 0.00 | 0.00% | 0.88 | 0.91 | 0.87 |
Nov 1, 2024 | 0.88 | 0.00 | 0.00% | 0.88 | 0.91 | 0.87 |
Oct 31, 2024 | 0.87 | -0.02 | -2.25% | 0.89 | 0.89 | 0.87 |
Oct 30, 2024 | 0.89 | -0.03 | -3.26% | 0.92 | 0.94 | 0.89 |
Oct 29, 2024 | 0.88 | -0.11 | -11.11% | 0.99 | 0.99 | 0.87 |
Oct 28, 2024 | 1.01 | 0.05 | 5.21% | 0.96 | 1.01 | 0.96 |
Oct 25, 2024 | 0.95 | -0.04 | -4.04% | 0.99 | 1.00 | 0.95 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Invivyd Inc. Company profile
About Adagio Therapeutics Inc
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The Company's initial focus is on the virus SARS-CoV-2, its variants and the disease caused by this virus, which is known as Coronavirus Infectious Disease (COVID-19). The Company is developing its lead product candidate, ADG20, for the treatment and prevention of coronavirus disease 2019 (COVID-19). ADG20 is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 including disease caused by variants, as either a single or combination agent. The Company is also evaluating broadly neutralizing antibodies, such as ADG10, for potential use in combination with ADG20 for COVID-19.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Adagio Therapeutics Inc revenues was not reported. Net loss increased from $48.1M to $143.7M. Higher net loss reflects Research and development increase from $7.3M to $110.9M (expense), Selling, general and administrative increase from $890K to $15.5M (expense), Stock-based Compensation in SGA increase from $2K to $6.3M (expense).
Industry: | Bio Therapeutic Drugs |
1601 Trapelo Road
Suite 178
WALTHAM
MASSACHUSETTS 02451
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com